KRISTEN JUBB: Open Payments
NPI 1598042848 · BEL AIR, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,090 in 98 payments from 19 companies in 2025. Trend: 2023 $823 · 2024 $2,465 · 2025 $2,090
Food & beverage: $1,986Education: $104
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $263 |
| Novartis Pharmaceuticals Corporation | 9 | $207 |
| Genentech USA, Inc. | 10 | $200 |
| GlaxoSmithKline, LLC. | 10 | $200 |
| GENZYME CORPORATION | 10 | $192 |
| Lilly USA, LLC | 6 | $149 |
| Amgen Inc. | 15 | $148 |
| CSL Behring | 4 | $119 |
| Regeneron Healthcare Solutions, Inc. | 5 | $113 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $99 |
Products named: DUPIXENT, Xolair, TEZSPIRE, NUCALA, AIRSUPRA, NEFFY, EBGLYSS, Rhapsido.
Industry payments across MD — which companies pay providers there.
